Inspira Technologies OXY B.H.N. Ltd. (IINN) Stock Score, Valuation & Financial Research

Inspira Technologies OXY B.H.N. Ltd. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for IINN

Inspira Technologies OXY B.H.N. Ltd. does not currently have a complete Wall Street Score. The stored market price is USD 1.05. These figures are a research snapshot, not a buy or sell recommendation.

What Inspira Technologies OXY B.H.N. Ltd. does

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacturing, and marketing of proprietary life support technologies for the treatment of acute respiratory failure in Israel. It offers INSPIRA ART100, a life support system used in procedures requiring cardiopulmonary bypass for six hours or less. It also offers additive manufactured electronics platform that enables 3D architecture for systems operating in dilution cryostats. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'anana, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Inspira Technologies is a commercial-stage medical device company that generates revenue through the development, commercialization, and sale of advanced respiratory support systems and blood monitoring technologies. The company operates by securing regulatory clearances for its proprietary devices, such as the INSPIRA ART100, and deploying these systems into clinical settings for cardiopulmonary bypass and other respiratory procedures, while also pursuing strategic partnerships and licensing opportunities to scale its market presence.

Products and services

  • The company's primary products include the FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass and the HYLA blood sensor platform for continuous, non-invasive monitoring.

Brands and product families

  • INSPIRA ART100 — Flagship FDA-cleared system for cardiopulmonary bypass. Source
  • HYLA — Proprietary blood sensor platform for continuous, non-invasive monitoring. Source

Customer types

Hospitals; Academic and research institutions.

Suppliers, materials and equipment

  • Contract manufacturing and component suppliers — The company relies on third-party manufacturers and suppliers for the production and assembly of its medical device components and systems. Source

Business strengths to evaluate

  • FDA-cleared product portfolio Source
  • Growing intellectual property portfolio Source

Business risks and research considerations

  • Regulatory approval and commercialization risks Source
  • Dependence on third-party manufacturers Source

Sources: Company research source · Contract manufacturing and component suppliers · Regulatory approval and commercialization risks

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

IINN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.05
Market capitalization:
25.29M (currency not supplied)
Revenue:
USD 289K
Net income:
USD -12.64M
Free cash flow:
USD -9.96M
Cash:
USD 3.16M
Total debt:
USD 480K
EPS:
USD -0.62

What stands out

  • Reported year-over-year revenue growth is +0.0%.
  • Free cash flow is USD -9.96M, negative for the stored period.
  • The balance sheet shows USD 3.16M of cash versus USD 480K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -3447.8% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -4373.0% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 2.68M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for IINN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can IINN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • How long can IINN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is IINN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for IINN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of IINN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research IINN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.